Lymphocyte Subpopulations in Peripheral Giant Cell Granuloma

NCT07551310 | Completed

• 1 other identifier: ATAUNI-PGCG-2026
• Study Type: observational
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

Peripheral giant cell granuloma (PGCG) is a non-neoplastic inflammatory lesion of gingival tissues. This study aims to evaluate and compare lymphocyte subpopulations in PGCG tissues and adjacent healthy gingival tissues obtained from the same individuals. A total of 28 systemically healthy, non-smoking patients diagnosed with PGCG are included in this study. Biopsy samples are collected during surgical excision of PGCG lesions, and corresponding healthy gingival tissues are obtained from the same patients. Immunohistochemical analysis is performed to assess lymphocyte subpopulations, including CD3, CD4, CD8, CD20, and CD79a. The proportions of these cells are compared between diseased and healthy tissues.

Conditions

Gingival Lesions; Gingival Enlargement; Peripheral Giant Cell Granuloma

Keywords

Lymphocyte Subpopulations; Immunohistochemistry; Gingival Tissue; Oral Pathology; Periodontal Disease; Inflammatory Lesions

Outcome Measures

Primary Outcomes (1)

• Proportion of Lymphocyte Subpopulations

  The proportion of CD3, CD4, CD8, CD20, and CD79a positive cells is determined by calculating the percentage of positively stained cells relative to the total number of counted cells in gingival tissue samples.

  At the time of tissue analysis (baseline)

Secondary Outcomes (1)

• CD4/CD8 Ratio

  At the time of tissue analysis (baseline)

Study Arms (2)

PGCG Tissue

Biopsy samples obtained from peripheral giant cell granuloma lesions during surgical excision.

Diagnostic Test: Immunohistochemical Analysis

Healthy Gingival Tissue

Biopsy samples obtained from adjacent healthy gingival tissues of the same patients.

Diagnostic Test: Immunohistochemical Analysis

Interventions

Immunohistochemical Analysis DIAGNOSTIC_TEST

Immunohistochemical staining is performed on gingival tissue samples to evaluate lymphocyte subpopulations, including CD3, CD4, CD8, CD20, and CD79a. The proportion of positively stained cells is determined by calculating the percentage of positive cells relative to the total number of counted cells.

Healthy Gingival Tissue; PGCG Tissue

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of 28 systemically healthy, non-smoking patients diagnosed with peripheral giant cell granuloma.

You may qualify if:

• Systemically healthy individuals Non-smokers Patients diagnosed with peripheral giant cell granuloma Individuals requiring surgical excision of PGCG Patients providing written informed consent

You may not qualify if:

• Presence of systemic diseases Smoking habit Use of medications associated with gingival enlargement History of periodontal treatment within the last 6 months Pregnant or lactating individuals

Sponsors & Collaborators

• Ataturk University: lead

Study Sites (1)

Ataturk University Faculty of Dentistry

Erzurum, Malatya, 5444155691, Turkey (Türkiye)

Location

Related Publications (1)

• Dilsiz A, Gürsan N, Aydın T. Immunohistochemical analysis of lymphocyte subpopulation in normal gingiva and peripheral giant cell granuloma. Journal of Clinical Periodontology. 2012;39(Suppl 13):97.

  RESULT

Related Links

• Related Info

Biospecimen

Retention: SAMPLES WITHOUT DNA

Gingival tissue biopsy samples obtained from peripheral giant cell granuloma lesions and adjacent healthy gingival tissues are retained and used for immunohistochemical analysis.

MeSH Terms

Conditions

Granuloma, Giant Cell; Gingival Hyperplasia; Periodontal Diseases

Condition Hierarchy (Ancestors)

Jaw Diseases; Musculoskeletal Diseases; Stomatognathic Diseases; Gingival Diseases; Mouth Diseases; Granuloma; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Gingival Overgrowth

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 18, 2026
• First Posted: April 24, 2026
• Study Start: January 1, 2026
• Primary Completion: March 1, 2026
• Study Completion: March 30, 2026
• Last Updated: April 24, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)